Assessment of Rheumatoid Arthritis Quality Process Measures and Associated Costs

Population Health Management

Volumn 20, Issue 1, 2017, Pages 31-40

  Brady, Brenna L ^a   Tkacz, Joseph ^a   Meyer, Roxanne ^b   Bolge, Susan C ^b   Ruetsch, Charles ^a  

^a Health Analytics LLC   (United States)

^b Janssen Scientific Affairs LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AMBULATORY CARE; ARTICLE; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITAL PATIENT; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; PRESCRIPTION; RHEUMATOID ARTHRITIS; COST; ECONOMICS; FACTUAL DATABASE; INSURANCE; PROCEDURES; STANDARDS; UNITED STATES;

ADULT; ARTHRITIS, RHEUMATOID; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE; UNITED STATES;

EID: 85010688887     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2015.0133     Document Type: Article

References (33)

1. Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep 2004;119:263-270.
2. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TI-CORA study): A single-blind randomised controlled trial. Lancet 2004;364(9430):263-269.
3. Holman H, Lorig K. Patients as partners in managing chronic disease: Partnership is a prerequisite for effective and efficient health care. BMJ 2000;320(7234):526-527.
4. Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum 1993;36:439-446.
5. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood) 2011;30:91-99.
6. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376(9746):1094-1108.
7. Prevoo ML, van Gestel AM, van T Hoff MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-1105.
8. Cardarelli WJ. Implications for managed care and specialty pharmacy in rheumatoid arthritis. Am J Manag Care 2012; 18(Suppl 13):S315-S324.
9. Bansback N, Marra CA, Finckh A, Anis A. The economics of treatment in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23(1):83-92.
10. Cooper NJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology (Oxford) 2000;39(1): 28-33.
11. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-639.
12. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-2762.
13. van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review Arthritis Care Res (Hoboken) 2011;63:65-78.
14. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline. Arthritis Rheum 1999; 42:1209-1218.
15. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-451.
16. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-914.
17. Pasma A, van't Spijker A, Hazes JM, Busschbach JJ, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: A systematic review. Semin Arthritis Rheum 2013;43(1):18-28.
18. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying an-tirheumatic drugs. Ann Rheum Dis 2010;69:964-975.
19. Tkacz J, Ellis LA, Meyer R, Bolge SC, Brady BL, Ruetsch C. Quality process measures for rheumatoid arthritis: Performance from members enrolled in a national health plan. J Manag Care Spec Pharm 2015;21:135-143.
20. Hussey PS, Wertheimer S, Mehrotra A. The association between health care quality and cost: A systematic review. Ann Intern Med 2013;158:27-34.
21. National Quality Forum. Guiding quality care. 2013. Available at: . Accessed October 29, 2013.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
23. Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:510-515.
24. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-528.
25. MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: Methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum 2004;51:193-202.
26. Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am J Med Qual 2006;21:269-275.
27. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006;295: 1912-1920.
28. Sidorov J, Shull R, Tomcavage J, Girolami S, Lawton N, Harris R. Does diabetes disease management save money and improve outcomes? A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria. Diabetes Care 2002;25:684-689.
29. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-822.
30. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-3035.
31. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-1841.
32. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myo-cardial infarction: Results from the Cooperative Cardiovascular Project. JAMA 1998;279:1351-1357.
33. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530.